Literature DB >> 19037972

Clinical review: the surgical treatment of idiopathic pseudotumour cerebri (idiopathic intracranial hypertension).

P W Brazis1.   

Abstract

To review the literature on the surgical treatment of idiopathic pseudotumour cerebri (PTC) [idiopathic intracranial hypertension (IIH)]. When medical therapy fails or when visual dysfunction deteriorates, surgical therapies for PTC should be considered. The main procedures performed include lumboperitoneal shunt (LPS), ventriculoperitoneal shunt (VPS) and optic nerve sheath fenestration (ONSF). Recently, venous sinus stenting procedures have been performed on selected patients with PTC, especially those with venous sinus occlusive disease. The literature is summarized and appraised in the form of a narrative review. It is evident that ONSF, LPS, VPS and, in selected cases, venous sinus stenting may improve vision and prevent deterioration of vision in patients with PTC. All of the procedures have their advantages and disadvantages and may fail with time no matter what procedure is used. Various authorities have vehemently advocated one or the other of these procedures. Until a prospective, randomized study comparing ONSF with LPS or VPS for PTC is performed, and until the role of venous sinus obstruction as the aetiology of PTC is better defined, the question of which surgical procedure is best for the treatment of PTC remains unanswered.

Entities:  

Mesh:

Year:  2008        PMID: 19037972     DOI: 10.1111/j.1468-2982.2008.01778.x

Source DB:  PubMed          Journal:  Cephalalgia        ISSN: 0333-1024            Impact factor:   6.292


  24 in total

1.  [Progressive blindness of a young female with extreme obesity].

Authors:  Th Bertelmann; W Sekundo
Journal:  Internist (Berl)       Date:  2010-09       Impact factor: 0.743

2.  An adolescent with suspected intracranial hypertension - ALL is not what it seems.

Authors:  Asgeir Store Jakola; Sasha Gulati
Journal:  Childs Nerv Syst       Date:  2012-01-28       Impact factor: 1.475

Review 3.  Sinus venous stenosis, intracranial hypertension and progression of primary headaches.

Authors:  Roberto De Simone; Angelo Ranieri; Silvana Montella; Mario Marchese; Pasquale Persico; Vincenzo Bonavita
Journal:  Neurol Sci       Date:  2012-05       Impact factor: 3.307

Review 4.  Is idiopathic intracranial hypertension without papilledema a risk factor for migraine progression?

Authors:  Roberto De Simone; Angelo Ranieri; Chiara Fiorillo; Leonilda Bilo; Vincenzo Bonavita
Journal:  Neurol Sci       Date:  2010-02-25       Impact factor: 3.307

5.  Transverse sinus stenting for idiopathic intracranial hypertension: a review of 52 patients and of model predictions.

Authors:  R M Ahmed; M Wilkinson; G D Parker; M J Thurtell; J Macdonald; P J McCluskey; R Allan; V Dunne; M Hanlon; B K Owler; G M Halmagyi
Journal:  AJNR Am J Neuroradiol       Date:  2011-07-28       Impact factor: 3.825

6.  A Possible Role for Temporary Lumbar Drainage in the Management of Idiopathic Intracranial Hypertension.

Authors:  Peter Gates; Peter McNeill
Journal:  Neuroophthalmology       Date:  2016-09-23

7.  Sinus venous stenosis-associated idiopathic intracranial hypertension without papilledema as a powerful risk factor for progression and refractoriness of headache.

Authors:  Roberto De Simone; Angelo Ranieri; Silvana Montella; Mario Marchese; Vincenzo Bonavita
Journal:  Curr Pain Headache Rep       Date:  2012-06

8.  A 24-year-old woman with rapidly progressing vision loss.

Authors:  Milad Modabber; Vasudha Gupta; Amadeo R Rodriguez
Journal:  Digit J Ophthalmol       Date:  2017-01-15

Review 9.  Update on the surgical management of idiopathic intracranial hypertension.

Authors:  Nisha Mukherjee; M Tariq Bhatti
Journal:  Curr Neurol Neurosci Rep       Date:  2014-03       Impact factor: 5.081

10.  Unilateral transverse sinus stenting of patients with idiopathic intracranial hypertension.

Authors:  M Bussière; R Falero; D Nicolle; A Proulx; V Patel; D Pelz
Journal:  AJNR Am J Neuroradiol       Date:  2009-11-26       Impact factor: 3.825

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.